Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of Formula (I):



Formula I

wherein A is an amino acid of Formula (II):





Formula II

wherein:

R_0 is H or CH_3;

~~R_1 = C(=O)OR_2;~~
~~C(O)NR_3R_4;~~
~~CH=N-Y;~~

~~$CH(NR_5R_6)R_7$;~~
~~$CH(OR_8)R_9$;~~
~~$CH(OR_{10})_2$;~~
~~$CH(SR_{12})_2$;~~
~~$CH=CHC(=O)Me$;~~
~~$CH_2CH_2C(=O)Me$;~~
~~$CH=CHCH(OR_{16})Me$;~~
~~$CH_2CH_2CH(OR_{16})Me$;~~
~~$CH=CHCH(NR_{17}R_{18})Me$;~~
~~$CH_2CH_2CH(NR_{17}R_{18})Me$;~~
~~$CH=CHC(=N-Y)Me$;~~
~~$CH_2CH_2C(=N-Y)Me$;~~
~~$CH=CHC(OR_{19})_2Me$;~~
~~$CH_2CH_2C(OR_{19})_2Me$;~~
~~CH_2-$CH_2C(=CR_{20}R_{21})Me$;~~
~~$CH=CHC(SR_{22})_2Me$;~~
~~$CH_2CH_2C(SR_{22})_2Me$;~~
~~$CH=CHC(=O)NR_{25}R_{26}$;~~
~~$CH_2CH_2C(=O)NR_{25}R_{26}$;~~
~~$CH=CHC(=O)OR_{26}$;~~
~~$CH_2CH_2C(=O)OR_{26}$;~~
~~$CH=CHC(=O)CH_2CH_2NR_{27}R_{28}$;~~
~~$CH_2CH_2C(=O)CH_2CH_2NR_{27}R_{28}$;~~
~~$CH=CHC(=O)CH=CHNR_{29}R_{30}$;~~
~~$CH_2CH_2C(=O)CH=CHNR_{29}R_{30}$;~~
~~$CH=CH-C(OR_{31})R_{32}Me$;~~
~~$CH_2CH_2C(OR_{31})R_{32}Me$;~~
~~$CH=CHC(=O)CH_2C(OH)R_{33}R_{34}$; or~~
~~$CH_2CH_2C(=O)CH_2C(OH)R_{33}R_{34}$;~~

~~R_2 and R_{26} are the same or different and independently selected from the group consisting of:~~
~~hydrogen;~~
~~C_1-C_6-straight alkyl chain;~~
~~C_3-C_6-straight alkenyl chain;~~
~~C_3-C_6-branched alkyl chain;~~
~~C_4-C_6-branched alkenyl chain;~~
~~C_3-C_6-straight alkynyl chain;~~
~~C_3-C_7-cycloalkyl;~~
~~CH_2-(C_3-C_7-cycloalkyl);~~
~~$(CH_2)_n$-aryl ring;~~
~~$(CH_2)_n$-heteroaryl ring;~~
~~CH_2OCH_3;~~
~~CH_2SCH_3;~~
~~CH_2CH_2F;~~
~~CH_2CF_3;~~
~~$CH_2CH_2CF_3$;~~
~~$CH(CF_3)_2$; and~~
~~$CH_2OCH_2OC(O)CH_3$;~~

~~R_3, R_4, R_5, R_6, R_{10}, R_{11}, R_{12}, R_{17}, R_{18}, R_{19}, R_{22}, R_{25}, R_{27}, R_{28}, R_{29}, and R_{30} are the same or different and independently selected from the group consisting of:~~

- ~~hydrogen;~~
- ~~C_1-C_6-straight alkyl chain;~~
- ~~C_2-C_6-straight alkenyl chain;~~
- ~~C_3-C_6-branched alkyl chain;~~
- ~~C_4-C_6-branched alkenyl chain;~~
- ~~C_2-C_6-straight alkynyl chain;~~
- ~~C_3-C_7-cycloalkyl;~~
- ~~CH_2-(C_3-C_7-cycloalkyl);~~
- ~~$(CH_2)_n$-aryl ring; and~~
- ~~$(CH_2)_n$-heteroaryl ring;~~

~~R_3 and R_4, R_5 and R_6, R_{10}, R_{12}, R_{17} and R_{18}, R_{19}, R_{22}, R_{25} and R_{26}, R_{27} and R_{28}, R_{29} and R_{30} are together -CH_2CH_2-, -$CH_2CH_2CH_2$-, -$CH_2CH_2CH_2CH_2$-, -$CH_2CH_2CH_2CH_2CH_2$- and -$CH_2CH_2CH_2CH_2CH_2CH_2$- that results in the formation of a cyclic moiety that contains the heteroatom or heteroatoms to which they are bound;~~

~~R_8, R_{16}, and R_{31} are the same or different and independently selected from the group consisting of:~~

- ~~hydrogen;~~
- ~~C_1-C_6-straight alkyl chain;~~
- ~~C_2-C_6-straight alkenyl chain;~~
- ~~C_3-C_6-branched alkyl chain;~~
- ~~C_4-C_6-branched alkenyl chain;~~
- ~~C_2-C_6-straight alkynyl chain;~~
- ~~C_3-C_7-cycloalkyl;~~
- ~~CH_2-(C_3-C_7-cycloalkyl);~~
- ~~$(CH_2)_n$-aryl ring;~~
- ~~$(CH_2)_n$-heteroaryl ring;~~
- ~~alkanoyl;~~
- ~~alkenoyl;~~
- ~~alkynoyl;~~
- ~~aryloyl;~~
- ~~arylalkanoyl;~~
- ~~alkylaminocarbonyl;~~
- ~~arylaminocarbonyl;~~
- ~~arylalkylaminocarbonyl;~~
- ~~alkyloxycarbonyl;~~
- ~~aryloxycarbonyl; and~~
- ~~arylalkyloxycarbonyl;~~

~~R_7, R_9, R_{13}, R_{14}, R_{15}, R_{20}, R_{21}, R_{23}, R_{24}, R_{32}, R_{33}, and R_{34}, are the same or different and independently selected from the group consisting of:~~

- ~~hydrogen;~~
- ~~deuterium;~~
- ~~halogen;~~
- ~~hydroxyl;~~
- ~~nitrile;~~

~~substituted and unsubstituted C_1-C_6-straight alkyl chain;~~
~~substituted and unsubstituted C_2-C_6-straight alkenyl chain;~~
~~substituted and unsubstituted C_3-C_6-branched alkyl chain;~~
~~substituted and unsubstituted C_4-C_6-branched alkenyl chain;~~
~~substituted and unsubstituted C_2-C_6-straight alkynyl chain;~~
~~substituted and unsubstituted C_4-C_6-branched alkynyl chain;~~
~~substituted and unsubstituted C_4-C_6-chain having alkenyl and alkynyl groups;~~
~~substituted and unsubstituted C_3-C_7-cycloalkyl;~~
~~substituted and unsubstituted $(CH_2)_p$-(C_3-C_7-cycloalkyl);~~
~~substituted and unsubstituted aryl;~~
~~substituted and unsubstituted heteroaryl;~~
~~substituted and unsubstituted arylalkyl;~~
~~substituted and unsubstituted heteroarylalkyl;~~
~~COOH;~~
~~$COOR_2$; and~~
~~$C(O)NR_3R_4$;~~

~~n = 0, 1, 2, 3 or 4;~~

~~p = 0, 1, 2, or 3;~~

X = hydrogen;
hydroxyl; or
hydroxyl group derivatized with an alkanoyl, aryloyl, alkylaminocarbonyl, arylaminocarbonyl, arylalkylaminocarbonyl, alkyloxycarbonyl, aryloxycarbonyl, or arylalkyloxycarbonyl group;

~~Y = C_1-C_6 straight and branched chain alkyl;~~
~~C_3-C_6 straight and branched chain alkenyl;~~
~~arylalkyl;~~
~~heteroarylalkyl;~~
~~C_1-C_6 straight and branched chain alkyloxy;~~
~~aryloxy;~~
~~acyloxy;~~
~~arylalkyloxy;~~
~~C_1-C_6 straight and branched chain alkylamino;~~
~~arylamino;~~
~~arylalkylamino;~~
~~heteroarylamino;~~
~~heteroarylalkylamino;~~
~~C_1-C_6 straight and branched chain alkylcarboxamido;~~
~~arylcarboxamido;~~
~~heteroarylcarboxamido;~~
~~C_1-C_6 straight and branched chain alkylsulfonamido;~~
~~arylsulfonamido;~~
~~arylalkylsulfonamido;~~
~~heteroarylsulfonamido;~~
~~heteroarylalkylsulfonamido; or~~
~~$NH_2C(O)NH$;~~

CO- in Formula II is covalently bound to an α-amino group of B in Formula I to form an amide linkage, and -N-R_0 in Formula II is covalently bound to a carboxylic acid of K to form an amide linkage;

B is an amino acid selected from the group consisting of:
α-aminobutyric acid;
alanine;
threonine;
valine;
norvaline; and
a modified α-aminobutyric acid, alanine, valine, or norvaline, wherein a carbon atom in a side chain is substituted with a hydroxyl group;

C is a sarcosine;

D is an amino acid selected from the group consisting of:
leucine;
N-methyl leucine;
valine;
γ-hydroxy-N-methyl leucine; and
γ-hydroxy leucine;

E is an amino acid selected from the group consisting of:
valine;
norvaline; and
a modified valine or norvaline, wherein a carbon atom in a side chain is substituted with a hydroxyl group;

F is an amino acid selected from the group consisting of:
leucine;
N-methyl leucine;
γ-hydroxy-N-methyl leucine; and
γ-hydroxy leucine;

G is α-aminobutyric acid or alanine;

H is D-alanine;

I and J are independently selected from the group consisting of:
leucine;
N-methyl leucine;
γ-hydroxy-N-methyl leucine; and
γ-hydroxy leucine;

K is N-methyl valine or valine;

or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (currently amended) A compound according to claim [[2]] 1, wherein the compound has the following formula:



4. (withdrawn – currently amended) A compound according to claim [[2]] 1, wherein the compound has the following formula:



5. (withdrawn – currently amended) A compound according to claim [[2]] 1, wherein the compound has the following formula:



6-75. (canceled).

76. (withdrawn – currently amended) A compound according to claim [[2]] 1, wherein the compound has the following formula:



Formula XI.

77-102. (canceled)

103. (original) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and one or more pharmaceutical excipients.

104-182. (canceled)

183. (withdrawn) A method of suppressing or reducing immune response in a mammal comprising:

administering a therapeutically effective amount of the compound of claim 1 to the said mammal under conditions effective to suppress immune response in a mammal.

184. (withdrawn) A method of treating a mammal with a chronic inflammatory or autoimmune disease comprising:

administering a therapeutically effective amount of the compound of claim 1 to the mammal under conditions effective to treat the chronic inflammatory or autoimmune disease.

185. (withdrawn) The method of claim 184, wherein the chronic inflammatory or autoimmune disease is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, psoriasis, and ulcerative colitis.

186. (withdrawn) A method of treating a mammal with a neurodegenerative disease comprising:

administering a therapeutically effective amount of the compound of claim 1 to the mammal under conditions effective to treat the neurodegenerative disease.

187. (withdrawn) The method of claim 186, wherein the neurogenerative disease is selected from the group consisting of diabetic neuropathy, amyotrophic lateral sclerosis, spinal cord injury, Alzheimer's disease, Parkinson's disease, and stroke.

188. (withdrawn) A method of treating a mammal with infectious diseases caused by HIV, fungal pathogens, or parasites, said method comprising:

administering a therapeutically effective amount of the compound of claim 1 to the mammal under conditions effective to treat the infectious disease.